RxDoctor Payments Data

Mary Qiu

Glaucoma Specialist · Cleveland, OHNPI 1972917292

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Nova Eye, Inc. accounts for 83.6% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $65,175, more than ten times the $234 reported in 2019.

$98,941in general payments, 2019–2025

Across 121 payments — averaging $817.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nova Eye, Inc.$83K
  • NEW World Medical,inc.$7K
  • AbbVie$5K
  • Sight Sciences, Inc.$985
  • Alcon$801
  • W. L. Gore & Associates, Inc.$783
  • plus $1K from 6 others

What the payments were for

  • Consulting fees$53,42454%
  • Speaking & faculty fees$3,4003%
  • Travel & lodging$30,72931%
  • Food & beverage$9,3529%
  • Education$2,0352%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$50,594
Medicare patients
149
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost33$14,930
Methazolamide37$11,880
LumiganBimatoprost12$9,775
Alphagan PBrimonidine Tartrate38$9,463
VyzultaLatanoprostene Bunod24$9,390
RhopressaNetarsudil Mesylate17$7,792
Dorzolamide-TimololDorzolamide/Timolol/Pf34$5,631
Brimonidine Tartrate114$3,386
Prednisolone Acetate66$3,169
Latanoprost160$2,302
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat149$2,049
Acetazolamide ErAcetazolamide15$801
Ketorolac Tromethamine20$798
Acetazolamide15$711
Timolol Maleate44$666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$139$22,72250 claims
AbbVieLumigan, Alphagan P$5,194$19,23850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →